中国临床药理学杂志2017，Vol.33Issue(17)：1631-1633,3.DOI:10.13699/j.cnki.1001-6821.2017.17.006
吉非替尼片联合康莱特胶囊治疗ⅢB/Ⅳ期非小细胞肺癌的临床研究
Clinical trial of gefitinib tablets combined with Kanglaite capsules in the treatment of stage ⅢB/Ⅳ non-small cell lung cancer
摘要
Abstract
Objective To observe the clinical efficacy and safety of gefitinib tablets combined with Kanglaite capsules in the treatment of stage Ⅲ B/Ⅳ non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) sensitive mutations.Methods Eighty patients of stage Ⅲ B/Ⅳ NSCLC with EGFR sensitive mutations were randomly divided into control group and treatment group with 40 cases per group.Control group was given gefitinib 250 mg · d-1,qd,oral.Treatment group received Kanglaite capsule 2.7 mg,qid,oral,on the basis of control group.Two groups were treated to tumor progression or intolerant.The clinical efficacy and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in control and treatment groups were 17.50％ (7/40 cases) and 7.50％ (3/40 cases),disease control rates (DCR) in control and treatment groups were 92.50％ (37/40 cases) and 87.50％ (35/40 cases),progress free survival in control and treatment groups were 17.7 months and 16.3 months,the differences were statistically significant (all P ＞ 0.05).The adverse drug reactions in treatment group were based on diarrhea,rash and loss of appetite,which in control group were based on diarrhea,rash and nausea.The incidences of adverse drug reactions in treatment and control groups were 60.00％ and 85.00％ with significant difference (P ＜ 0.05).Conclusion Gefitinib tablet combined with Kanglaite capsule can reduce the incidence of adverse drug reaction,and maybe extend the progress free survival.关键词
康莱特胶囊/吉非替尼片/非小细胞肺癌/安全性Key words
Kanglaite capsule/gefitinib tablet/non-small cell lung cancer/safety分类
医药卫生引用本文复制引用
王俊艳,魏素菊,洪雷,张帆,刘承媛,孔雁..吉非替尼片联合康莱特胶囊治疗ⅢB/Ⅳ期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2017,33(17):1631-1633,3.基金项目
河北省科技支撑计划基金资助项目(13277752D) （13277752D）
